Drugs / VYD2311
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06523153 | Aug 2024 → May 2025 overdue | COVID-19 | Invivyd, Inc. | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07655180 Comparator | Jun → Aug 2026 overdue | COVID-19 | Invivyd, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07298434 Comparator | Jan → Aug 2026 overdue | COVID-19 | Invivyd, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VYD2311 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07298434 ↗ |
| Modality | Monoclonal antibody | “VYD2311, a monoclonal antibody targeting SARS-CoV-2” NCT06523153 ↗ |
| Route | Intramuscular | “single IV, IM, or SC administration” NCT06523153 ↗ |
| Route | Intravenous | “single IV, IM, or SC administration” NCT06523153 ↗ |
| Route | Subcutaneous | “single IV, IM, or SC administration” NCT06523153 ↗ |